{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:37:58Z","timestamp":1787614678006,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12985-019-1140-x","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T09:03:24Z","timestamp":1552554204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4\u20135 chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Mingshu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7994-5362","authenticated-orcid":false,"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"issue":"4","key":"1140_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0272-6386(03)00024-6","volume":"41","author":"K Kasuno","year":"2003","unstructured":"Kasuno K, Ono T, Matsumori A, Nogaki F, Kusano H, Watanabe H, Yodoi J, Muso E. Hepatitis C virus-associated tubulointerstitial injury. Am J Kidney Dis. 2003;41(4):767\u201375.","journal-title":"Am J Kidney Dis"},{"key":"1140_CR2","volume-title":"GUIDELINES FOR THE CARE AND TREATMENT OF PERSONS DIAGNOSED WITH CHRONIC HEPATITIS C VIRUS INFECTION","author":"WHO","year":"2018","unstructured":"WHO. GUIDELINES FOR THE CARE AND TREATMENT OF PERSONS DIAGNOSED WITH CHRONIC HEPATITIS C VIRUS INFECTION. 2018."},{"issue":"6","key":"1140_CR3","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","volume":"65","author":"RB Fissell","year":"2004","unstructured":"Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335\u201342.","journal-title":"Kidney Int"},{"issue":"9","key":"1140_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","volume":"19","author":"F Fabrizi","year":"2012","unstructured":"Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19(9):601\u20137.","journal-title":"J Viral Hepat"},{"issue":"10","key":"1140_CR5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","volume":"14","author":"F Fabrizi","year":"2007","unstructured":"Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14(10):697\u2013703.","journal-title":"J Viral Hepat"},{"issue":"6","key":"1140_CR6","doi-asserted-by":"publisher","first-page":"e100790","DOI":"10.1371\/journal.pone.0100790","volume":"9","author":"JJ Lee","year":"2014","unstructured":"Lee JJ, Lin MY, Chang JS, Hung CC, Chang JM, Chen HC, Yu ML, Hwang SJ. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9(6):e100790.","journal-title":"PLoS One"},{"issue":"20","key":"1140_CR7","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889\u201398.","journal-title":"N Engl J Med"},{"issue":"27","key":"1140_CR8","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599\u2013607.","journal-title":"N Engl J Med"},{"issue":"20","key":"1140_CR9","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878\u201387.","journal-title":"N Engl J Med"},{"issue":"6","key":"1140_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","volume":"70","author":"T Isakova","year":"2017","unstructured":"Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, Bansal V, Rosas SE, Nigwekar S, Yee J, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737\u201351.","journal-title":"Am J Kidney Dis"},{"key":"1140_CR11","volume-title":"sovaldi_pi","author":"Gilead","year":"2017","unstructured":"Gilead. sovaldi_pi. 2017."},{"issue":"2","key":"1140_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"key":"1140_CR13","volume-title":"HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C","author":"AASLD, IDSA","year":"2018","unstructured":"AASLD, IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2018."},{"issue":"7","key":"1140_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"1140_CR15","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"G Wells","year":"2016","unstructured":"Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2016."},{"key":"1140_CR16","volume-title":"Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Review Group reviews: Planning the analysis at protocol stage","author":"R Ryan","year":"2014","unstructured":"Ryan R. Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Review Group reviews: Planning the analysis at protocol stage; 2014."},{"issue":"23","key":"1140_CR17","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1002\/sim.1091","volume":"20","author":"DB Petitti","year":"2001","unstructured":"Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med. 2001;20(23):3625\u201333.","journal-title":"Stat Med"},{"issue":"12","key":"1140_CR18","first-page":"2065","volume":"32","author":"J Dumortier","year":"2017","unstructured":"Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, Gagnieu MC, Grange JD, Minello A, Guillaud O, et al. Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant. 2017;32(12):2065\u201371.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1140_CR19","first-page":"23","volume":"5","author":"A Aggarwal","year":"2017","unstructured":"Aggarwal A, Yoo ER, Perumpail RB, Cholankeril G, Kumari R, Daugherty TJ, Lapasaran AS, Ahmed A. Sofosbuvir use in the setting of end-stage renal disease: a single center experience. J Clin Transl Hepatol. 2017;5(1):23\u20136.","journal-title":"J Clin Transl Hepatol"},{"key":"1140_CR20","doi-asserted-by":"publisher","unstructured":"Bera C, Das P, Pal S. Safety and efficacy of Sofosbuvir based regimen on patients with end stage renal disease\u2014a single Centre experience. J Clin Exp Hepatol. 2017;7:S29. https:\/\/doi.org\/10.1016\/j.jceh.2017.05.061","DOI":"10.1016\/j.jceh.2017.05.061"},{"issue":"2","key":"1140_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12664-017-0735-7","volume":"36","author":"NS Choudhary","year":"2017","unstructured":"Choudhary NS, Kumar A, Bodh V, Bansal SB, Sharma R, Jain M, Saigal S, Saraf N. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol. 2017;36(2):113\u20136.","journal-title":"Indian J Gastroenterol"},{"issue":"5","key":"1140_CR22","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1007\/s10620-018-4979-6","volume":"63","author":"S Taneja","year":"2018","unstructured":"Taneja S, Duseja A, De A, Mehta M, Ramachandran R, Kumar V, Kohli HS, Gupta KL, Dhiman RK, Chawla Y. Low-dose Sofosbuvir is safe and effective in treating chronic hepatitis C in patients with severe renal impairment or end-stage renal disease. Dig Dis Sci. 2018;63(5):1334\u201340.","journal-title":"Dig Dis Sci"},{"key":"1140_CR23","doi-asserted-by":"publisher","unstructured":"Goel A, Bhadauria DS, Kaul A, Verma P, Mehrotra M, Gupta A, Sharma RK, Rai P, Aggarwal R. Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with eGFR <30 ml\/min. Nephrology (Carlton). 2019 Mar;24(3):316\u201321. https:\/\/doi.org\/10.1111\/nep.13222 .","DOI":"10.1111\/nep.13222"},{"key":"1140_CR24","first-page":"583A","volume":"66","author":"Y He","year":"2017","unstructured":"He Y, Chen T, Zhao Y. Safety, efficacy and tolerance of half-dose sofosbuvir plus daclatasvir in treatment of acute hepatitis C infection in patients with end-stage renal disease on hemodialysis: a prospective, single-center, open-label study. Hepatology. 2017;66:583A.","journal-title":"Hepatology"},{"issue":"2","key":"1140_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/hdi.12604","volume":"22","author":"M Surendra","year":"2018","unstructured":"Surendra M, Raju SB, Sridhar N, Vijay Kiran B, Rajesh G, Anvesh G, Raju N. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: a prospective observational study. Hemodial Int. 2018;22(2):217\u201321.","journal-title":"Hemodial Int"},{"issue":"5","key":"1140_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/nep.13050","volume":"23","author":"MS Akhil","year":"2018","unstructured":"Akhil MS, Kirushnan B, Martin M, Arumugam K, Ganesh Prasad NK, Ravichandran R. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: a retrospective study. Nephrology (Carlton). 2018;23(5):446\u201352.","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"1140_CR27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/tri.12799","volume":"29","author":"S Beinhardt","year":"2016","unstructured":"Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, Stattermayer AF, Stauber R, Strasser M, Zoller H, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int. 2016;29(9):999\u20131007.","journal-title":"Transpl Int"},{"key":"1140_CR28","doi-asserted-by":"crossref","unstructured":"Manoj K, Nayak SL, Gupta E, Kataria A, Sarin SK. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. Liver Int. 2018;38:2137\u201348.","DOI":"10.1111\/liv.13863"},{"key":"1140_CR29","doi-asserted-by":"publisher","unstructured":"Nazario HE, Modi AA, Ndungu M, Ramirez R, Tujague L, Weinstein JS. Excellent cure rates in largest ESRD patient cohort who completed treatment with full dose, daily sofosbuvir-based regimens. J Hepatol. 2017;66(1):S507. https:\/\/doi.org\/10.1016\/S0168-8278(17)31414-9","DOI":"10.1016\/S0168-8278(17)31414-9"},{"key":"1140_CR30","doi-asserted-by":"crossref","unstructured":"Saab S, AJ M, NB S, Choi G, Durazo FA, ME-K M, Han SB, Busuttil RW. Use of Sofosbuvir-based treatment of chronic hepatitis C in liver transplant recipients on hemodialysis. J Clin Gastroenterol. 2017;51(2):167\u201373.","DOI":"10.1097\/MCG.0000000000000640"},{"issue":"3","key":"1140_CR31","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","volume":"63","author":"KR Bhamidimarri","year":"2015","unstructured":"Bhamidimarri KR, Czul F, Peyton A, Levy C, Hernandez M, Jeffers L, Roth D, Schiff E, O'Brien C, Martin P. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63(3):763\u20135.","journal-title":"J Hepatol"},{"issue":"1","key":"1140_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","volume":"65","author":"A Desnoyer","year":"2016","unstructured":"Desnoyer A, Pospai D, Le MP, Gervais A, Heurgue-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65(1):40\u20137.","journal-title":"J Hepatol"},{"issue":"Suppl 1587","key":"1140_CR33","first-page":"848A","volume":"66-1","author":"E Lawitz","year":"2017","unstructured":"Lawitz E, Landis CS, Maliakkal BJ, Bonacini M, Ortiz-Lasanta G, Zhang J, Mogalian E, De-Oertel S, Osinusi AO, Brainard DM, et al. Safety and Efficacy of Treatment with Once-Daily Ledipasvir\/Sofosbuvir (90\/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients with Severe Renal Impairment. Hepatology. 2017;66-1(Suppl 1587):848A.","journal-title":"Hepatology"},{"issue":"Suppl 1181","key":"1140_CR34","first-page":"635A","volume":"66-1","author":"SC Gordon","year":"2017","unstructured":"Gordon SC, Ahmed A, Saab S, Dieterich DT, Wong RJ, Kugelmas M, Brown KA, Younossi ZM. Health Outcomes Associated with Sofosbuvir-based Single-Tablet Regimens for Initial and Re-treatment of Chronic Hepatitis C in the US. Hepatology. 2017;66-1(Suppl 1181):635A.","journal-title":"Hepatology"},{"issue":"3","key":"1140_CR35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/hep4.1035","volume":"1","author":"P Cox-North","year":"2017","unstructured":"Cox-North P, Hawkins KL, Rossiter ST, Hawley MN, Bhattacharya R, Landis CS. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun. 2017;1(3):248\u201355.","journal-title":"Hepatol Commun"},{"issue":"1","key":"1140_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","volume":"3","author":"T McQuaid","year":"2015","unstructured":"McQuaid T, Savini C, Seyedkazemi S. Sofosbuvir, a significant paradigm change in HCV treatment. J Clin Transl Hepatol. 2015;3(1):27\u201335.","journal-title":"J Clin Transl Hepatol."},{"issue":"5","key":"1140_CR37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/1744-9987.12407","volume":"20","author":"R Miyazaki","year":"2016","unstructured":"Miyazaki R, Miyagi K. Effect and safety of Daclatasvir-Asunaprevir combination therapy for chronic hepatitis C virus genotype 1b -infected patients on hemodialysis. Ther Apher Dial. 2016;20(5):462\u20137.","journal-title":"Ther Apher Dial"},{"issue":"7","key":"1140_CR38","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","volume":"150","author":"PJ Pockros","year":"2016","unstructured":"Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, Cohen DE, Shulman NS, Wang D, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150(7):1590\u20138.","journal-title":"Gastroenterology."},{"issue":"10003","key":"1140_CR39","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londono MC, Hassanein T, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537\u201345.","journal-title":"Lancet."},{"issue":"7","key":"1140_CR40","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/liv.13336","volume":"37","author":"T Li","year":"2017","unstructured":"Li T, Qu Y, Guo Y, Wang Y, Wang L. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver Int. 2017;37(7):974\u201381.","journal-title":"Liver Int"},{"issue":"6","key":"1140_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5527\/wjn.v5.i6.547","volume":"5","author":"S Gadde","year":"2016","unstructured":"Gadde S, Lee B, Kidd L, Zhang R. Antineutrophil cytoplasmic antibodies crescentic allograft glomerulonephritis after sofosbuvir therapy. World J Nephrol. 2016;5(6):547\u201350.","journal-title":"World J Nephrol"},{"issue":"1","key":"1140_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ajg.2015.391","volume":"111","author":"R Wanchoo","year":"2016","unstructured":"Wanchoo R, Thakkar J, Schwartz D, Jhaveri KD. Harvoni (Ledipasvir with Sofosbuvir)-induced renal injury. Am J Gastroenterol. 2016;111(1):148\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 867","key":"1140_CR43","first-page":"428A","volume":"64-1","author":"F Durand","year":"2016","unstructured":"Durand F, Pianko S, Ni L, De-Oertel S, McNally J, Brainard DM, McHutchison JG, Schiff ER, Colombo M. Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients with Mild or Moderate Renal Impairment. Hepatology. 2016;64-1(Suppl 867):428A.","journal-title":"Hepatology"},{"issue":"Suppl 770","key":"1140_CR44","first-page":"380A","volume":"64-1","author":"L Telep","year":"2016","unstructured":"Telep L, Brown A, Brainard DM, Chokkalingam AP. Assessment of risk of acute kidney injury associated with exposure to sofosbuvir-containing HCV treatment regimens and HCV infection. Hepatology. 2016;64-1(Suppl 770):380A.","journal-title":"Hepatology"},{"issue":"1","key":"1140_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/apt.14799","volume":"48","author":"AA Butt","year":"2018","unstructured":"Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB. Effectiveness, treatment completion and safety of sofosbuvir\/ledipasvir and paritaprevir\/ritonavir\/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. Aliment Pharmacol Ther. 2018;48(1):35\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1140_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12664-018-0833-1","volume":"37","author":"R Mehta","year":"2018","unstructured":"Mehta R, Desai K, Kabrawala M, Nandwani S, Shah J, Desai N, Parekh V. Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis. Indian J Gastroenterol. 2018;37(1):72\u20133.","journal-title":"Indian J Gastroenterol"},{"key":"1140_CR47","doi-asserted-by":"publisher","unstructured":"Saxena V, Koraishy FM, Sise M, Lim JK, Chung RT, Liapakis A, Nelson DR, Schmidt M, Fried MW, Terrault N. LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target. J Hepatol. 2015;62:S267. https:\/\/doi.org\/10.1016\/S0168-8278(15)30162-8","DOI":"10.1016\/S0168-8278(15)30162-8"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-019-1140-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-019-1140-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-019-1140-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T16:09:52Z","timestamp":1721059792000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-019-1140-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1186\/s12985-019-1140-x","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"8 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MSL works for Gilead while concurrently enrolled in Ph.D.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"34"}}